Florida Senate
-
2025
CS for CS for CS for SB 196
By
the Committee on Rules; the Appropriations Committee on
Agriculture, Environment, and General Government; the Committee
on Regulated Industries; and Senators Gruters and Calatayud
595-03665-25 2025196c3
First Engrossed
2025196e1
1 A bill to be entitled
10 unchanged paragraphs
2 An act relating to chemicals in consumer products;
3 amending s. 499.003, F.S.; revising the definition of
4 the term “drug”; defining the term “vaccine or vaccine
5 material”; amending s. 499.007, F.S.; deeming a drug
6 misbranded if it is a food containing a vaccine or
7 vaccine material, but its label does not include
8 specified information; creating s. 499.0095, F.S.;
9 defining terms; requiring that, beginning on a
10 specified date, cosmetics manufactured, sold, offered
11 or distributed for sale, or distributed for use in
12 this state provide notice of specified added
13 ingredients on a website that is created and
14 maintained by the cosmetics manufacturer and made
15 available to the public regarding such added
1316 ingredients; onprohibiting, theby single-usea packagingspecified of suchdate,
17 cosmetics that release formaldehyde from being
18 manufactured, sold, offered or distributed for sale,
19 or distributed for use in this state, unless it is a
20 natural byproduct with no functional or technical
21 purpose; providing an exception; providing
1422 cosmeticsconstruction; prohibiting,providing bypenalties aand specified date, cosmeticsremedies;
15 that release formaldehyde from being manufactured,
16 sold, offered or distributed for sale, or distributed
23 providing applicability; authorizing the Department of
24 Business and Professional Regulation to adopt rules;
25 amending s. 500.03, F.S.; defining the term “messenger
26 ribonucleic acid vaccine” or “mRNA vaccine”; amending
27 s. 500.04, F.S.; prohibiting the use of fruits and
28 vegetables to deliver an mRNA vaccine; amending s.
29 500.11, F.S.; deeming a food misbranded if it contains
1730 fora usevaccine inor thisvaccine statematerial, unlessbut itits islabel adoes naturalnot
18 byproduct with no functional or technical purpose;
31 include specified information; amending ss. 499.01 and
1932 providing499.05, anF.S.; exceptionconforming cross-references; providing construction;
20 providing penalties and remedies; providing
21 applicability; authorizing the Department of Business
22 and Professional Regulation to adopt rules; amending
23 s. 500.03, F.S.; defining the term “messenger
24 ribonucleic acid vaccine” or “mRNA vaccine”; amending
25 s. 500.04, F.S.; prohibiting the use of fruits and
26 vegetables to deliver an mRNA vaccine; amending s.
27 500.11, F.S.; deeming a food misbranded if it contains
28 a vaccine or vaccine material, but its label does not
29 include specified information; amending ss. 499.01 and
30 499.05, F.S.; conforming cross-references; providing
3133 an effective date.
32
33 Be It Enacted by the Legislature of the State of Florida:
34
35 Be It Enacted by the Legislature of the State of Florida:
36
3537 Section 1. Present subsections (47), (48), and (49) of
3638 section 499.003, Florida Statutes, are redesignated as
3739 subsections (48), (49), and (50), respectively, a new subsection
3840 (47) is added to that section, and subsections (17) and (40) of
3941 that section are amended, to read:
4042 499.003 Definitions of terms used in this part.—As used in
4143 this part, the term:
4244 (17) “Drug” means an article that is:
4345 (a) Recognized in the current edition of the United States
4446 Pharmacopoeia and National Formulary, official Homeopathic
4547 Pharmacopoeia of the United States, or any supplement to any of
4648 those publications;
4749 (b) Intended for use in the diagnosis, cure, mitigation,
4850 treatment, therapy, or prevention of disease in humans or other
4951 animals;
5052 (c) Intended to affect the structure or any function of the
5153 body of humans or other animals;
or
5254 (d) Intended for use as a component of any article
5355 specified in paragraph (a), paragraph (b), or paragraph (c), and
5456 includes active pharmaceutical ingredients, but does not include
5557 devices or their nondrug components, parts, or accessories
; or
5658
(e)
Food
as defined in s. 500.03 which
contains a vaccine
5759
or vaccine material
.
5860 (40) “Prescription drug” means a prescription, medicinal,
5961 or legend drug, including, but not limited to, finished dosage
6062 forms or active pharmaceutical ingredients subject to, defined
6163 by, or described by s. 503(b) of the federal act or s. 465.003,
6264 s. 499.007(13), subsection (31), or subsection
(48)
(47)
, except
6365 that an active pharmaceutical ingredient is a prescription drug
6466 only if substantially all finished dosage forms in which it may
6567 be lawfully dispensed or administered in this state are also
6668 prescription drugs.
6769
(4
7
)
“Vaccine or vaccine material” means a substance
68
70
authorized or approved by the United States
3 unchanged paragraphs
F
ood and
D
rug
69
71
A
dministration
which is
intended for use in humans to stimulate
7072
the production of antibodies and provide immunity against
7173
disease
and
which is
prepared from the causative agent of a
7274
disease, its products, or a synthetic substitute
and is
treated
7375
to act as an antigen without inducing the disease.
7476 Section 2. Present subsection (17) of section 499.007,
7577 Florida Statutes, is redesignated as subsection (18), and a new
7678 subsection (17) is added to that section, to read:
7779 499.007 Misbranded drug or device.—A drug or device is
7880 misbranded:
79
81
(17)
If it is a food as defined in s. 500.03 and contains a
8082
vaccine or vaccine material, but its label does not bear,
in
8183
type of uniform size and prominence, the words “contains vaccine
8284
or vaccine material”
3 unchanged paragraphs
and does not
specif
y
that the food is
8385
classified as a drug under the Florida Drug and Cosmetic Act
.
8486 Section 3. Section 499.0095, Florida Statutes, is created
8587 to read:
8688
499.00
95
Presence of certain ingredients in cosmetics;
8789
notice required
.—
88
90
(1)
As used in this section, the term:
8991
(a) “Incidental ingredient” means a substance that has no
9092
technical or functional effect in the cosmetics but is present
9193
by reason of having been incorporated into the cosmetics as an
9294
ingredient of another cosmetic ingredient.
9395
(b) “Ingredient” means:
9496
1. Any chemical or mixture of chemicals intentionally used
9597
in the manufacturing of cosmetics. The term does not include any
9698
incidental ingredient that is present in cosmetics at
9799
insignificant levels or that has no technical or functional
98
100
effect; or
99
101
2. A processing aid, including any of the following:
100102
a. A substance that is used in the processing of cosmetics
101103
but is removed from the cosmetics in accordance with good
102104
manufacturing practices before the cosmetics are packaged in
103105
their finished form.
104106
b. A substance that is used in the processing of cosmetics
105107
for its technical or functional effect to produce the cosmetics
106108
and is then converted to a substance the same as constituents of
107109
a declared ingredient, in accordance with good manufacturing
108110
practices, and does not significantly increase the concentration
109
111
of such constituents before the cosmetics are packaged in their
110112
finished form.
111113
c. A substance that is used in the processing of cosmetics
112114
for its technical or functional effect to produce the cosmetics
113115
in accordance with good manufacturing practices, that is present
114116
in the cosmetics’ finished form at insignificant concentrations,
115117
and that does not have any technical or functional effect in
116118
such cosmetics.
117119
(
c
)
“Ortho-phthalates” means esters of ortho-phthalic acid.
118
120
(
3 unchanged paragraphs
d
)
“Perfluoroalkyl and polyfluoroalkyl substances”
or
119121
“PFAS
”
means a class of fluorinated organic chemicals containing
120122
at least one fully fluorinated carbon atom.
121123
(2)
4 unchanged paragraphs
Except as provided in subsection (
5
), beginning J
uly
1,
122124
202
6
,
cosmetics manufactured, sold, offered or distributed for
123125
sale, or distributed for use in this state must provide notice
124
on such cosmetics’ single-use packaging of the following
125
intentionally added chemicals or chemical classes:
126
(a)
Ortho-phthalates
.
on a website that is created and maintained by the cosmetics
127
(b)
PFAS.
manufacturer and made available to the public regarding the
128
(c)
Formaldehyde
as identified in CAS 50-00-0.
following intentionally added chemicals or chemical classes:
129
(d)
Methylene glycol
as identified in CAS 463-57-0.
(a) Ortho-phthalates.
130
(e)
Mercury
as identified in CAS 7439-97-6.
(b) PFAS.
131
(f)
Triclosan
(c) Formaldehyde as identified in CAS 3380-34-550-00-0.
132
(g
)
M
-phenylenediamine
or
its salt
derivatives as
(d) Methylene glycol as identified in CAS 463-57-0.
133
(e) Mercury as identified in CAS 7439-97-6.
134
(f) Triclosan as identified in CAS 3380-34-5.
135
(g) M-phenylenediamine or its salt derivatives as
136
identified in CAS 108-45-2.
134
(h)
O
-phenylenediamine
or
its salt
derivatives as
135
identified in CAS 95-54-5
.
136
(
3
)
Except as provided in subsection (
5
), beginning J
ul
y 1,
137
202
6
,
cosmetic
s manufactured, sold, offered or distributed for
(h) O-phenylenediamine or its salt derivatives as
138
sale, or distributed for use in this state
must provide notice
identified in CAS 95-54-5.
139
on such cosmetics’ single-use packaging
of
any
lead or lead
(3) Except as provided in subsection (5), beginning July 1,
140
2026, cosmetics manufactured, sold, offered or distributed for
141
sale, or distributed for use in this state must provide notice
142
on a website that is created and maintained by the cosmetics
143
manufacturer and made available to the public regarding any lead
144
or lead
compounds
as identified by CAS 7439-92-1, whether
145
intentionally added
141
added
or naturally occurring,
3 unchanged paragraphs
at
10
part
s
per
146
per million or
more
,
142
, or as otherwise determined by department
rule.
143147
(4) Except as provided in subsection (5), beginning July 1,
144148
2026, cosmetics manufactured, sold, offered or distributed for
145149
sale, or distributed for use in this state may not release
146
150
formaldehyde as identified in paragraph (2)(c) unless it is a
147
151
natural byproduct with no functional or technical purpose.
148
152
(
3 unchanged paragraphs
5
)
A retailer
in possession of cosmetics that do not
149
153
comply with the requirements of this section as of July 1, 2026,
150154
may exhaust its existing stock through sales to the public until
151155
J
3 unchanged paragraphs
uly
1, 202
7
.
152156
(
3 unchanged paragraphs
6
)
A violation of this section is
subject to the penalties
153157
and remedies provided in s.
499.066.
154158
(
3 unchanged paragraphs
7
)
This section does not apply to
cosmetic products
155159
regulated as drugs by the United States Food and Drug
156160
Administration.
157
161
(8)
The department
may
adopt rules necessary to implement
158
162
this section.
159163 Section 4. Present paragraphs (t) through (z) of subsection
160164 (1) of section 500.03, Florida Statutes, are redesignated as
161165 paragraphs (u) through (aa), respectively, and a new paragraph
162166 (t) is added to that subsection, to read:
163167 500.03 Definitions; construction; applicability.—
164168 (1) For the purpose of this chapter, the term:
165169
(t) “Messenger ribonucleic acid vaccine”
or “mRNA vaccine”
166
170
means a vaccine that uses laboratory-produced messenger
167171
ribonucleic acid to trigger the human body’s immune system to
168
172
generate an immune response.
169173 Section 5. Subsection (12) is added to section 500.04,
170174 Florida Statutes, to read:
171175 500.04 Prohibited acts.—The following acts and the causing
172176 thereof within the state are prohibited:
173177
(12)
The use of a fruit or vegetable as a delivery
174178
mechanism for an
mRNA
vaccine as defined in s. 500.03.
175179 Section 6. Paragraph (q) is added to subsection (1) of
176180 section 500.11, Florida Statutes, to read:
177181 500.11 Food deemed misbranded.—
178182 (1) A food is deemed to be misbranded:
179
183
(q)
If it contains a vaccine or vaccine material as defined
180184
in s. 499.003, unless its label bears,
in type of uniform size
181185
and prominence, the words
“contains vaccine or vaccine material”
182186
and specifies that the food is classified as a drug under the
183187
Florida Drug and Cosmetic Act
.
184188 Section 7. Paragraphs (a), (b), and (h) of subsection (2)
185189 of section 499.01, Florida Statutes, are amended to read:
186190 499.01 Permits.—
187191 (2) The following permits are established:
188192 (a)
Prescription drug manufacturer permit.
—A prescription
189193 drug manufacturer permit is required for any person that is a
190194 manufacturer of a prescription drug and that manufactures or
191195 distributes such prescription drugs in this state.
192196 1. A person that operates an establishment permitted as a
193197 prescription drug manufacturer may engage in distribution of
194198 prescription drugs for which the person is the manufacturer and
195199 must comply with s. 499.0121 and all other provisions of this
196200 part and rules adopted under this part. The department shall
197201 adopt rules for issuing a virtual prescription drug manufacturer
198202 permit to a person who engages in the manufacture of
199203 prescription drugs but does not make or take physical possession
200204 of any prescription drugs. The rules adopted by the department
201205 under this section may exempt virtual manufacturers from certain
202206 establishment, security, and storage requirements set forth in
203207 s. 499.0121.
204208 2. A prescription drug manufacturer must comply with all
205209 appropriate state and federal good manufacturing practices.
206210 3. A blood establishment, as defined in s. 381.06014,
207211 operating in a manner consistent with the provisions of 21
208212 C.F.R. parts 211 and 600-640, and manufacturing only the
209213 prescription drugs described in
s. 499.003(49)(j)
s.
210214
499.003(48)(j)
is not required to be permitted as a prescription
211215 drug manufacturer under this paragraph or to register products
212216 under s. 499.015.
213217 (b)
Prescription drug repackager permit.
—A prescription
214218 drug repackager permit is required for any person that
215219 repackages a prescription drug in this state.
216220 1. A person that operates an establishment permitted as a
217221 prescription drug repackager may engage in distribution of
218222 prescription drugs repackaged at that establishment and must
219223 comply with all of the provisions of this part and the rules
220224 adopted under this part that apply to a prescription drug
221225 manufacturer.
222226 2. A prescription drug repackager must comply with all
223227 appropriate state and federal good manufacturing practices.
224228 3. A prescription drug repackager permit is not required
225229 for distributing medicinal drugs or prepackaged drug products
226230 between entities under common control which each hold either an
227231 active Class III institutional pharmacy permit under chapter 465
228232 or an active health care clinic establishment permit under
229233 paragraph (r). For purposes of this subparagraph, the term
230234 “common control” has the same meaning as in
s. 499.003(49)(a)3.
231235
s. 499.003(48)(a)3.
232236 (h)
Restricted prescription drug distributor permit.
—
233237 1. A restricted prescription drug distributor permit is
234238 required for:
235239 a. Any person located in this state who engages in the
236240 distribution of a prescription drug, which distribution is not
237241 considered “wholesale distribution” under
s. 499.003(49)(a)
s.
238
242
499.003(48)(a)
.
239243 b. Any person located in this state who engages in the
240244 receipt or distribution of a prescription drug in this state for
241245 the purpose of processing its return or its destruction if such
242246 person is not the person initiating the return, the prescription
243247 drug wholesale supplier of the person initiating the return, or
244248 the manufacturer of the drug.
245249 c. A blood establishment located in this state which
246250 collects blood and blood components only from volunteer donors
247251 as defined in s. 381.06014 or pursuant to an authorized
248252 practitioner’s order for medical treatment or therapy and
249253 engages in the wholesale distribution of a prescription drug not
250254 described in
s. 499.003(49)(j)
s. 499.003(48)(j)
to a health
251255 care entity. A mobile blood unit operated by a blood
252256 establishment permitted under this sub-subparagraph is not
253257 required to be separately permitted. The health care entity
254258 receiving a prescription drug distributed under this sub
255259 subparagraph must be licensed as a closed pharmacy or provide
256260 health care services at that establishment. The blood
257261 establishment must operate in accordance with s. 381.06014 and
258262 may distribute only:
259263 (I) Prescription drugs indicated for a bleeding or clotting
260264 disorder or anemia;
261265 (II) Blood-collection containers approved under s. 505 of
262266 the federal act;
263267 (III) Drugs that are blood derivatives, or a recombinant or
264268 synthetic form of a blood derivative;
265269 (IV) Prescription drugs that are identified in rules
266270 adopted by the department and that are essential to services
267271 performed or provided by blood establishments and authorized for
268272 distribution by blood establishments under federal law; or
269273 (V) To the extent authorized by federal law, drugs
270274 necessary to collect blood or blood components from volunteer
271275 blood donors; for blood establishment personnel to perform
272276 therapeutic procedures under the direction and supervision of a
273277 licensed physician; and to diagnose, treat, manage, and prevent
274278 any reaction of a volunteer blood donor or a patient undergoing
275279 a therapeutic procedure performed under the direction and
276280 supervision of a licensed physician, as long as all of the
277281 health care services provided by the blood establishment are
278282 related to its activities as a registered blood establishment or
279283 the health care services consist of collecting, processing,
280284 storing, or administering human hematopoietic stem cells or
281285 progenitor cells or performing diagnostic testing of specimens
282286 if such specimens are tested together with specimens undergoing
283287 routine donor testing. The blood establishment may purchase and
284288 possess the drugs described in this sub-subparagraph without a
285289 health care clinic establishment permit.
286290 2. Storage, handling, and recordkeeping of these
287291 distributions by a person required to be permitted as a
288292 restricted prescription drug distributor must be in accordance
289293 with the requirements for wholesale distributors under s.
290294 499.0121.
291295 3. A person who applies for a permit as a restricted
292296 prescription drug distributor, or for the renewal of such a
293297 permit, must provide to the department the information required
294298 under s. 499.012.
295299 4. The department may adopt rules regarding the
296300 distribution of prescription drugs by hospitals, health care
297301 entities, charitable organizations, other persons not involved
298302 in wholesale distribution, and blood establishments, which rules
299303 are necessary for the protection of the public health, safety,
300304 and welfare.
301305 5. A restricted prescription drug distributor permit is not
302306 required for distributions between pharmacies that each hold an
303307 active permit under chapter 465, have a common ownership, and
304308 are operating in a freestanding end-stage renal dialysis clinic,
305309 if such distributions are made to meet the immediate emergency
306310 medical needs of specifically identified patients and do not
307311 occur with such frequency as to amount to the regular and
308312 systematic supplying of that drug between the pharmacies. The
309313 department shall adopt rules establishing when the distribution
310314 of a prescription drug under this subparagraph amounts to the
311315 regular and systematic supplying of that drug.
312316 6. A restricted prescription drug distributor permit is not
313317 required for distributing medicinal drugs or prepackaged drug
314318 products between entities under common control that each hold
315319 either an active Class III institutional pharmacy permit under
316320 chapter 465 or an active health care clinic establishment permit
317321 under paragraph (r). For purposes of this subparagraph, the term
318322 “common control” has the same meaning as in
s. 499.003(49)(a)3.
319
323
s. 499.003(48)(a)3.
320324 Section 8. Paragraphs (i) and (l) of subsection (1) of
321325 section 499.05, Florida Statutes, are amended to read:
322326 499.05 Rules.—
323327 (1) The department shall adopt rules to implement and
324328 enforce this chapter with respect to:
325329 (i) Additional conditions that qualify as an emergency
326330 medical reason under
s. 499.003(49)(b)2.
s. 499.003(48)(b)2.
or
327331 s. 499.82.
328332 (l) The recordkeeping, storage, and handling with respect
329333 to each of the distributions of prescription drugs specified in
330334
s. 499.003(49)(a)-(v)
s. 499.003(48)(a)-(v)
or s. 499.82(14).
331335 Section 9. This act shall take effect July 1, 2025.